Aug. 9 (Bloomberg) -- U.S. regulators disclosed a safety review of AstraZeneca Plc's top-selling acid-reflex drugs Nexium and Prilosec after two small studies linked the medicines to heart attacks and death. AstraZeneca shares fell the most in three months.
